Real-world application of nirmatrelvir/ritonavir in hospitalized COVID-19 patients with onset of symptoms beyond 5 days: a comparative study
Purpose Physicians may administer Nirmatrelvir-ritonavir to patients who have been symptomatic for more than 5 days. There is currently no clear evidence to support this approach. Methods A real-world study was conducted to investigate the potential relationship between the administration of Nirmatr...
Gespeichert in:
| Veröffentlicht in: | Infection 2024-08, Vol.52 (4), p.1519-1525 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1525 |
|---|---|
| container_issue | 4 |
| container_start_page | 1519 |
| container_title | Infection |
| container_volume | 52 |
| creator | Luo, Wen Li, Ke-Yi Dai, Chunmei Zhu, Wenliang Lin, Juan Lu, Fang Chen, Qiujuan Wang, Wanyu Zhuang, Qihong Lin, Yihua |
| description | Purpose
Physicians may administer Nirmatrelvir-ritonavir to patients who have been symptomatic for more than 5 days. There is currently no clear evidence to support this approach.
Methods
A real-world study was conducted to investigate the potential relationship between the administration of Nirmatrelvir-ritonavir and the rates of intubation or in-hospital mortality among COVID-19 patients who experienced symptoms for more than 5 days. The end point was a composite event of intubation or in-hospital mortality. The outcomes between those patients who received Nirmatrelvir-ritonavir and those who did not were compared.
Results
A total of 847 patients were included in the analysis. Among them, 312 patients (36.84%) received Nirmatrelvir-ritonavir. Within the entire population, 86 patients (10.15%) experienced intubation or in-hospital mortality. The main analysis indicated that there was a significant association between the application of Nirmatrelvir-ritonavir and intubation or in-hospital mortality, with an odds ratio of 0.50 (95% confidence interval, 0.28 to 0.87;
P
= 0.0153) using inverse probability of treatment weighting. The finding was consistent with multiple sensitivity analyses.
Conclusions
The application of Nirmatrelvir-ritonavir was associated with a significantly reduced risk of intubation or death in hospitalized COVID-19 patients who experienced symptoms for more than 5 days as compared to those who did not receive the treatment. |
| doi_str_mv | 10.1007/s15010-024-02255-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3045116927</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3045116927</sourcerecordid><originalsourceid>FETCH-LOGICAL-c370t-9bef34cc5ef82e174ef37abcb1d86c74621c90c4c617b9075d2da3f89291adb83</originalsourceid><addsrcrecordid>eNp9kc1uFSEYhonR2GP1BlwYEjdusPwOgztz_GvSpIlRt4QBxtLMwAhMm_EevAevxSuTeqomLlwQIDzP-5G8ADwm-DnBWJ4UIjDBCFPeFhUC8TtgRzhTCCvJ7oIdZhijntDuCDwo5RJjLBSX98ER6ztBm7ID3957M6HrlCcHzbJMwZoaUoRphDHk2dTsp6uQT3KoKZp2giHCi1SWUM0UvnoH9-efTl8houDSTB9rgdehXsAUi683MWWbl5rmAge_peig-PHdma28gAbaNC8mN-3Kw1JXtz0E90YzFf_odj8GH9-8_rB_h87O357uX54hyySuSA1-ZNxa4ceeeiJ5u0oz2IG4vrOSd5RYhS23HZGDwlI46gwbe0UVMW7o2TF4dshdcvqy-lL1HIr102SiT2vRDHNBSKeobOjTf9DLtObYfteoviO9kJQ2ih4om1Mp2Y96yWE2edME65uy9KEs3crSv8rSvElPbqPXYfbuj_K7nQawA1DaU_zs89_Z_4n9CdGdohs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3086185722</pqid></control><display><type>article</type><title>Real-world application of nirmatrelvir/ritonavir in hospitalized COVID-19 patients with onset of symptoms beyond 5 days: a comparative study</title><source>SpringerNature Journals</source><creator>Luo, Wen ; Li, Ke-Yi ; Dai, Chunmei ; Zhu, Wenliang ; Lin, Juan ; Lu, Fang ; Chen, Qiujuan ; Wang, Wanyu ; Zhuang, Qihong ; Lin, Yihua</creator><creatorcontrib>Luo, Wen ; Li, Ke-Yi ; Dai, Chunmei ; Zhu, Wenliang ; Lin, Juan ; Lu, Fang ; Chen, Qiujuan ; Wang, Wanyu ; Zhuang, Qihong ; Lin, Yihua</creatorcontrib><description>Purpose
Physicians may administer Nirmatrelvir-ritonavir to patients who have been symptomatic for more than 5 days. There is currently no clear evidence to support this approach.
Methods
A real-world study was conducted to investigate the potential relationship between the administration of Nirmatrelvir-ritonavir and the rates of intubation or in-hospital mortality among COVID-19 patients who experienced symptoms for more than 5 days. The end point was a composite event of intubation or in-hospital mortality. The outcomes between those patients who received Nirmatrelvir-ritonavir and those who did not were compared.
Results
A total of 847 patients were included in the analysis. Among them, 312 patients (36.84%) received Nirmatrelvir-ritonavir. Within the entire population, 86 patients (10.15%) experienced intubation or in-hospital mortality. The main analysis indicated that there was a significant association between the application of Nirmatrelvir-ritonavir and intubation or in-hospital mortality, with an odds ratio of 0.50 (95% confidence interval, 0.28 to 0.87;
P
= 0.0153) using inverse probability of treatment weighting. The finding was consistent with multiple sensitivity analyses.
Conclusions
The application of Nirmatrelvir-ritonavir was associated with a significantly reduced risk of intubation or death in hospitalized COVID-19 patients who experienced symptoms for more than 5 days as compared to those who did not receive the treatment.</description><identifier>ISSN: 0300-8126</identifier><identifier>ISSN: 1439-0973</identifier><identifier>EISSN: 1439-0973</identifier><identifier>DOI: 10.1007/s15010-024-02255-4</identifier><identifier>PMID: 38652225</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Antiretroviral drugs ; Antiviral drugs ; Comparative studies ; Confidence intervals ; COVID-19 ; Family Medicine ; General Practice ; Health services ; Hospitals ; Infectious Diseases ; Internal Medicine ; Intubation ; Medicine ; Medicine & Public Health ; Mortality ; Patients ; Risk analysis ; Risk management ; Risk reduction ; Ritonavir ; Sensitivity analysis ; Statistical analysis</subject><ispartof>Infection, 2024-08, Vol.52 (4), p.1519-1525</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. Springer-Verlag GmbH Germany, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c370t-9bef34cc5ef82e174ef37abcb1d86c74621c90c4c617b9075d2da3f89291adb83</cites><orcidid>0000-0002-9354-7704</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s15010-024-02255-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s15010-024-02255-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,781,785,27929,27930,41493,42562,51324</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38652225$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Luo, Wen</creatorcontrib><creatorcontrib>Li, Ke-Yi</creatorcontrib><creatorcontrib>Dai, Chunmei</creatorcontrib><creatorcontrib>Zhu, Wenliang</creatorcontrib><creatorcontrib>Lin, Juan</creatorcontrib><creatorcontrib>Lu, Fang</creatorcontrib><creatorcontrib>Chen, Qiujuan</creatorcontrib><creatorcontrib>Wang, Wanyu</creatorcontrib><creatorcontrib>Zhuang, Qihong</creatorcontrib><creatorcontrib>Lin, Yihua</creatorcontrib><title>Real-world application of nirmatrelvir/ritonavir in hospitalized COVID-19 patients with onset of symptoms beyond 5 days: a comparative study</title><title>Infection</title><addtitle>Infection</addtitle><addtitle>Infection</addtitle><description>Purpose
Physicians may administer Nirmatrelvir-ritonavir to patients who have been symptomatic for more than 5 days. There is currently no clear evidence to support this approach.
Methods
A real-world study was conducted to investigate the potential relationship between the administration of Nirmatrelvir-ritonavir and the rates of intubation or in-hospital mortality among COVID-19 patients who experienced symptoms for more than 5 days. The end point was a composite event of intubation or in-hospital mortality. The outcomes between those patients who received Nirmatrelvir-ritonavir and those who did not were compared.
Results
A total of 847 patients were included in the analysis. Among them, 312 patients (36.84%) received Nirmatrelvir-ritonavir. Within the entire population, 86 patients (10.15%) experienced intubation or in-hospital mortality. The main analysis indicated that there was a significant association between the application of Nirmatrelvir-ritonavir and intubation or in-hospital mortality, with an odds ratio of 0.50 (95% confidence interval, 0.28 to 0.87;
P
= 0.0153) using inverse probability of treatment weighting. The finding was consistent with multiple sensitivity analyses.
Conclusions
The application of Nirmatrelvir-ritonavir was associated with a significantly reduced risk of intubation or death in hospitalized COVID-19 patients who experienced symptoms for more than 5 days as compared to those who did not receive the treatment.</description><subject>Antiretroviral drugs</subject><subject>Antiviral drugs</subject><subject>Comparative studies</subject><subject>Confidence intervals</subject><subject>COVID-19</subject><subject>Family Medicine</subject><subject>General Practice</subject><subject>Health services</subject><subject>Hospitals</subject><subject>Infectious Diseases</subject><subject>Internal Medicine</subject><subject>Intubation</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mortality</subject><subject>Patients</subject><subject>Risk analysis</subject><subject>Risk management</subject><subject>Risk reduction</subject><subject>Ritonavir</subject><subject>Sensitivity analysis</subject><subject>Statistical analysis</subject><issn>0300-8126</issn><issn>1439-0973</issn><issn>1439-0973</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kc1uFSEYhonR2GP1BlwYEjdusPwOgztz_GvSpIlRt4QBxtLMwAhMm_EevAevxSuTeqomLlwQIDzP-5G8ADwm-DnBWJ4UIjDBCFPeFhUC8TtgRzhTCCvJ7oIdZhijntDuCDwo5RJjLBSX98ER6ztBm7ID3957M6HrlCcHzbJMwZoaUoRphDHk2dTsp6uQT3KoKZp2giHCi1SWUM0UvnoH9-efTl8houDSTB9rgdehXsAUi683MWWbl5rmAge_peig-PHdma28gAbaNC8mN-3Kw1JXtz0E90YzFf_odj8GH9-8_rB_h87O357uX54hyySuSA1-ZNxa4ceeeiJ5u0oz2IG4vrOSd5RYhS23HZGDwlI46gwbe0UVMW7o2TF4dshdcvqy-lL1HIr102SiT2vRDHNBSKeobOjTf9DLtObYfteoviO9kJQ2ih4om1Mp2Y96yWE2edME65uy9KEs3crSv8rSvElPbqPXYfbuj_K7nQawA1DaU_zs89_Z_4n9CdGdohs</recordid><startdate>20240801</startdate><enddate>20240801</enddate><creator>Luo, Wen</creator><creator>Li, Ke-Yi</creator><creator>Dai, Chunmei</creator><creator>Zhu, Wenliang</creator><creator>Lin, Juan</creator><creator>Lu, Fang</creator><creator>Chen, Qiujuan</creator><creator>Wang, Wanyu</creator><creator>Zhuang, Qihong</creator><creator>Lin, Yihua</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9354-7704</orcidid></search><sort><creationdate>20240801</creationdate><title>Real-world application of nirmatrelvir/ritonavir in hospitalized COVID-19 patients with onset of symptoms beyond 5 days: a comparative study</title><author>Luo, Wen ; Li, Ke-Yi ; Dai, Chunmei ; Zhu, Wenliang ; Lin, Juan ; Lu, Fang ; Chen, Qiujuan ; Wang, Wanyu ; Zhuang, Qihong ; Lin, Yihua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c370t-9bef34cc5ef82e174ef37abcb1d86c74621c90c4c617b9075d2da3f89291adb83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antiretroviral drugs</topic><topic>Antiviral drugs</topic><topic>Comparative studies</topic><topic>Confidence intervals</topic><topic>COVID-19</topic><topic>Family Medicine</topic><topic>General Practice</topic><topic>Health services</topic><topic>Hospitals</topic><topic>Infectious Diseases</topic><topic>Internal Medicine</topic><topic>Intubation</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mortality</topic><topic>Patients</topic><topic>Risk analysis</topic><topic>Risk management</topic><topic>Risk reduction</topic><topic>Ritonavir</topic><topic>Sensitivity analysis</topic><topic>Statistical analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Luo, Wen</creatorcontrib><creatorcontrib>Li, Ke-Yi</creatorcontrib><creatorcontrib>Dai, Chunmei</creatorcontrib><creatorcontrib>Zhu, Wenliang</creatorcontrib><creatorcontrib>Lin, Juan</creatorcontrib><creatorcontrib>Lu, Fang</creatorcontrib><creatorcontrib>Chen, Qiujuan</creatorcontrib><creatorcontrib>Wang, Wanyu</creatorcontrib><creatorcontrib>Zhuang, Qihong</creatorcontrib><creatorcontrib>Lin, Yihua</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Luo, Wen</au><au>Li, Ke-Yi</au><au>Dai, Chunmei</au><au>Zhu, Wenliang</au><au>Lin, Juan</au><au>Lu, Fang</au><au>Chen, Qiujuan</au><au>Wang, Wanyu</au><au>Zhuang, Qihong</au><au>Lin, Yihua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Real-world application of nirmatrelvir/ritonavir in hospitalized COVID-19 patients with onset of symptoms beyond 5 days: a comparative study</atitle><jtitle>Infection</jtitle><stitle>Infection</stitle><addtitle>Infection</addtitle><date>2024-08-01</date><risdate>2024</risdate><volume>52</volume><issue>4</issue><spage>1519</spage><epage>1525</epage><pages>1519-1525</pages><issn>0300-8126</issn><issn>1439-0973</issn><eissn>1439-0973</eissn><abstract>Purpose
Physicians may administer Nirmatrelvir-ritonavir to patients who have been symptomatic for more than 5 days. There is currently no clear evidence to support this approach.
Methods
A real-world study was conducted to investigate the potential relationship between the administration of Nirmatrelvir-ritonavir and the rates of intubation or in-hospital mortality among COVID-19 patients who experienced symptoms for more than 5 days. The end point was a composite event of intubation or in-hospital mortality. The outcomes between those patients who received Nirmatrelvir-ritonavir and those who did not were compared.
Results
A total of 847 patients were included in the analysis. Among them, 312 patients (36.84%) received Nirmatrelvir-ritonavir. Within the entire population, 86 patients (10.15%) experienced intubation or in-hospital mortality. The main analysis indicated that there was a significant association between the application of Nirmatrelvir-ritonavir and intubation or in-hospital mortality, with an odds ratio of 0.50 (95% confidence interval, 0.28 to 0.87;
P
= 0.0153) using inverse probability of treatment weighting. The finding was consistent with multiple sensitivity analyses.
Conclusions
The application of Nirmatrelvir-ritonavir was associated with a significantly reduced risk of intubation or death in hospitalized COVID-19 patients who experienced symptoms for more than 5 days as compared to those who did not receive the treatment.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>38652225</pmid><doi>10.1007/s15010-024-02255-4</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-9354-7704</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-8126 |
| ispartof | Infection, 2024-08, Vol.52 (4), p.1519-1525 |
| issn | 0300-8126 1439-0973 1439-0973 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3045116927 |
| source | SpringerNature Journals |
| subjects | Antiretroviral drugs Antiviral drugs Comparative studies Confidence intervals COVID-19 Family Medicine General Practice Health services Hospitals Infectious Diseases Internal Medicine Intubation Medicine Medicine & Public Health Mortality Patients Risk analysis Risk management Risk reduction Ritonavir Sensitivity analysis Statistical analysis |
| title | Real-world application of nirmatrelvir/ritonavir in hospitalized COVID-19 patients with onset of symptoms beyond 5 days: a comparative study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T08%3A43%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Real-world%20application%20of%20nirmatrelvir/ritonavir%20in%20hospitalized%20COVID-19%20patients%20with%20onset%20of%20symptoms%20beyond%205%C2%A0days:%20a%20comparative%20study&rft.jtitle=Infection&rft.au=Luo,%20Wen&rft.date=2024-08-01&rft.volume=52&rft.issue=4&rft.spage=1519&rft.epage=1525&rft.pages=1519-1525&rft.issn=0300-8126&rft.eissn=1439-0973&rft_id=info:doi/10.1007/s15010-024-02255-4&rft_dat=%3Cproquest_cross%3E3045116927%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3086185722&rft_id=info:pmid/38652225&rfr_iscdi=true |